Ignite Creation Date:
2025-12-24 @ 12:58 PM
Ignite Modification Date:
2026-01-07 @ 7:04 AM
Study NCT ID:
NCT02658461
Status:
COMPLETED
Last Update Posted:
2016-04-29
First Post:
2016-01-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-02
Start Date Type:
None
Primary Completion Date:
2013-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-02
Completion Date Type:
ACTUAL
First Submit Date:
2016-01-11
First Submit QC Date:
None
Study First Post Date:
2016-01-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-02-18
Results First Submit QC Date:
None
Results First Post Date:
2016-03-25
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-03-28
Last Update Post Date:
2016-04-29
Last Update Post Date Type:
ESTIMATED